VERA

Vera Therapeutics, Inc. (VERA) 10Y Growth Potential Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-08-01

Overall Score

Business Quality

VERA continues to show deeply negative profitability and returns, with ROA at -75.4%, ROE at -84.1%, and ROIC at -85.8%.

Margins remain effectively zero across gross, operating, EBITDA, pretax, and net profit lines, indicating no current earnings power.

Financial Strength

The balance sheet remains liquid, with a current ratio of 10.9x and cash ratio of 1.01x.

Leverage is modest, with debt-to-equity at 0.18x and debt-to-assets at 0.14x, while net debt to EBITDA is near flat at -0.07x.

Working capital is positive at $479.2M, supporting near-term flexibility despite weak operating cash generation.

Growth Runway

There is no visible revenue or margin expansion signal in the current metrics, with revenue per share reported at 0 and operating metrics still negative.

The company’s cash conversion cycle remains highly distorted at 6,106.9 days, suggesting no evidence of scalable operating momentum.

Valuation

Traditional earnings and cash-flow valuation multiples are not meaningful because EBITDA, operating cash flow, and free cash flow remain negative.

Book-based valuation is the main anchor, with price-to-book at 5.17x and price-to-fair-value at 5.17x, which does not indicate a clear deep-value setup.

Momentum

No recent news or fresh operating catalyst is present to improve the near-term setup.

The latest data still reflects a business with negative earnings and cash flow, limiting momentum visibility.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →